GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts rate GoodRx “Hold” overall: Three rate it a sell, six a hold and four a buy, with an average 12-month price target of approximately $4.23.
• Insiders have been selling shares: Major shareholder Francisco Partners sold about 1.3 million shares for $4.54 million, while insiders sold 2.76 million shares worth $9.67 million over the past 90 days.
• Quarterly results were mixed: GoodRx met the $0.08 EPS consensus and exceeded revenue expectations with $200.4 million, but revenue declined 1.3% year over year; the stock recently traded at $3.48.

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given a consensus recommendation of "Hold" by the thirteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.2273.

A number of research firms have recently issued reports on GDRX. The Goldman Sachs Group restated a "neutral" rating and issued a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. Citigroup lifted their price target on GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Barclays upped their price target on GoodRx from $3.00 to $4.00 and gave the company an "underweight" rating in a research report on Thursday, August 20th. Weiss Ratings raised GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. Finally, TD Cowen raised their price objective on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th.

Insider Buying and Selling at GoodRx

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders sold 2,760,995 shares of company stock valued at $9,673,207. 5.87% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Technology Crossover Management X Ltd. purchased a new position in shares of GoodRx during the 2nd quarter valued at $4,762,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of GoodRx during the fourth quarter worth $1,585,000. LSV Asset Management raised its holdings in shares of GoodRx by 20.0% during the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company's stock worth $7,658,000 after acquiring an additional 471,319 shares in the last quarter. Prescott Group Capital Management L.L.C. acquired a new stake in GoodRx during the fourth quarter valued at $4,812,000. Finally, Northwestern Mutual Wealth Management Co. boosted its position in GoodRx by 10,242.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company's stock valued at $4,072,000 after purchasing an additional 1,488,137 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Price Performance

GDRX stock opened at $3.48 on Tuesday. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The company's 50 day simple moving average is $3.30 and its 200-day simple moving average is $2.73. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The firm has a market capitalization of $1.19 billion, a P/E ratio of 87.02, a P/E/G ratio of 1.73 and a beta of 1.59.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. During the same quarter in the prior year, the firm earned $0.09 EPS. The firm's quarterly revenue was down 1.3% on a year-over-year basis. As a group, equities research analysts anticipate that GoodRx will post 0.16 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.